...
首页> 外文期刊>Computational and Structural Biotechnology Journal >Systems biology analysis identifies TNFRSF9 as a functional marker of tumor-infiltrating regulatory T-cell enabling clinical outcome prediction in lung cancer
【24h】

Systems biology analysis identifies TNFRSF9 as a functional marker of tumor-infiltrating regulatory T-cell enabling clinical outcome prediction in lung cancer

机译:系统生物学分析将TNFRSF9鉴定为肿瘤浸润调节T细胞的功能标志物,从而实现肺癌临床结果预测的临床结果预测

获取原文
           

摘要

Regulatory T cells (Tregs) are enriched in the tumor microenvironment and play key roles in immune evasion of cancer cells. Cell surface markers specific for tumor-infiltrating Tregs (TI-Tregs) can be effectively targeted to enhance antitumor immunity and used for stratification of immunotherapy outcomes. Here, we present a systems biology approach to identify functional cell surface markers for TI-Tregs. We selected differentially expressed genes for surface proteins of TI-Tregs and compared these with other CD4 T cells using bulk RNA-sequencing data from murine lung cancer models. Thereafter, we filtered for human orthologues with conserved expression in TI-Tregs using single-cell transcriptome data from patients with non-small cell lung cancer (NSCLC). To evaluate the functional importance of expression-based markers of TI-Tregs, we utilized network-based measure of context-associated centrality in a Treg-specific coregulatory network. We identified TNFRSF9 (also known as 4-1BB or CD137 ), a previously reported target for enhancing antitumor immunity, among the final candidates for TI-Treg markers with high functional importance score. We found that the low TNFRSF9 expression level in Tregs was associated with enhanced overall survival rate and response to anti-PD-1 immunotherapy in patients with NSCLC, proposing that TNFRSF9 promotes immune suppressive activity of Tregs in tumor. Collectively, these results demonstrated that integrative transcriptome and network analysis can facilitate the discovery of functional markers of tumor-specific immune cells to develop novel therapeutic targets and biomarkers for boosting cancer immunotherapy.
机译:调节性T细胞(Tregs)在肿瘤微环境中富集,并在免疫毒物细胞中起关键作用。可以有效地靶向用于肿瘤浸润的Tregs(Ti-Tregs)的细胞表面标志物以增强抗肿瘤免疫,并用于免疫疗法结果的分层。在这里,我们提出了一种系统生物学方法来识别Ti-Tregs的功能细胞表面标记。我们选择了Ti-Tregs的表面蛋白的差异表达基因,并使用来自鼠肺癌模型的本体RNA测序数据与其他CD4 T细胞进行比较。此后,我们通过来自非小细胞肺癌(NSCLC)患者的单细胞转录组数据,在Ti-Tregs中过滤人体直向性。为了评估Ti-Tregs的表达式的基于表达式的功能的重要性,我们利用了基于网络相关的中心的基于网络相关的中心的度量。我们鉴定了TNFRSF9(也称为4-1BB或CD137),先前报道的靶向增强抗肿瘤免疫的靶标,其中TI-Treg标志物的最终候选者具有高功能重要性评分。我们发现Tregs中的低TNFRSF9表达水平与NSCLC患者的增强的总存活率和对抗PD-1免疫疗法的反应相关,提出TNFRSF9促进Tregs在肿瘤中的免疫抑制活性。总的来说,这些结果表明,一体化转录组和网络分析可以促进肿瘤特异性免疫细胞的功能标志物,以开发新的治疗靶标和生物标志物,用于促进癌症免疫疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号